Palm Beach, FL – May 22, 2019 – Analysts at Piper Jaffray say we could be looking at a global market value of between $250 billion to $500 billion a year. “We believe the long-term growth can be significant — both from transitioning illicit trade to legal sales, medical sales, and from transitioning sales in health [and] wellness categories to CBD-infused products.” Some of the top companies in the industry include RavenQuest BioMed Inc. (CSE:RQB)(OTC:RVVQF), OrganiGram Holdings Inc. (TSX-V:OGI) (NASDAQ:OGI), Harvest One Cannabis Inc. (TSX-V:HVT)(OTC:HRVOF), The Green Organic Dutchman Holdings Ltd. (TSX:TGOD)(OTC:TGODF), and The Supreme Cannabis Company Inc. (TSX:FIRE)(OTC:SPRWF).
RavenQuest BioMed Inc. (CSE:RQB)(OTCQB:RVVQF) BREAKING NEWS: RavenQuest BioMed Inc. just announced that it signed a Heads of Agreement with Norway’s s Cannabis BioCare A/ to enter into a joint venture to construct cannabis production facilities using RavenQuest’s Orbital Garden grow technology in certain geographic regions. It is anticipated that production facilities will be constructed within twenty-four months, with the capacity to produce up to 35,000 kilograms of cannabis annually.
“Our organization has quietly and patiently conducted research as a pre-cursor to entry into the global cannabis marketplace. Our due diligence process has been exhaustive and has involved conversations with several Canadian cannabis companies including five companies with market capitalizations in the billions of dollars. Ultimately, we chose to partner with one of the most scientific, innovative and fundamentally sound cannabis projects worldwide, namely RavenQuest BioMed,” said Cannabis Biocare founder, Gerhard Ludvigsen. Read more news for RQB at https://rqbglobal.com/category/news/
Other cannabis-related developments from around the markets include:
OrganiGram Holdings Inc. (TSX-V: OGI.V) (NASDAQ:OGI) just announced that it applied to list its common shares on the NASDAQ Global Select Market. In advance of anticipated listing on the NASDAQ, Organigram will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company’s common shares on the NASDAQ remains subject to the approval of the NASDAQ and the satisfaction of all applicable listing and regulatory requirements. The Company will continue to maintain the listing of its common shares on the TSX Venture Exchange under the symbol “OGI”.
“As a management team we are seeing increased interest from investors in the U.S. and internationally and believe that having a listing on the NASDAQ will facilitate trading” says Paolo De Luca, Chief Financial Officer of Organigram. “In addition, based on precedents in the cannabis space, we expect trading volumes to increase which should result in increased liquidity for all investors”.
Harvest One Cannabis Inc. (TSX-V:HVT)(OTCQX:HRVOF) just acquired 52% interest in Greenbelt Greenhouse Ltd. an Ontario private company located in Hamilton, Ontario. This strategic acquisition will supply Harvest One with high quality greenhouse grown cannabis from Greenbelt’s 152,000 sq. ft. facility which will primarily be dedicated to Harvest One’s expanding cannabis-infused health, wellness, and self-care products under the Dream Water and Satipharm brands, and expanding products resulting from the recently announced acquisition of Delivra, following the closing of that transaction. The Transaction ensures that Harvest One remains a vertically integrated house of brands by controlling the production of cannabis through cultivation and extraction, and ultimately to packaged good for consumers.
The Green Organic Dutchman Holdings Ltd. (TSX:TGOD)(OTCQX:TGODF) just announced that it has obtained approval from Health Canada, under the Cannabis Regulations, to expand operations into its new building located in Hamilton, Ontario. The 20,000 square feet indoor facility is going to be used for cannabis cultivation; planting will start in the coming weeks. “This is yet another important milestone for our team as we continue to ramp up production with a focus on executional excellence,” commented Brian Athaide, CEO of TGOD. “We have pioneered the concept of sustainably growing all-natural, certified organic cannabis at scale. The product we are able to offer Canadians is clean, pesticide-free and undeniably premium.”
The Supreme Cannabis Company Inc. (TSX: FIRE)(OTCQX: SPRWF) just announced that its wholly-owned subsidiary, 7ACRES obtained Health Canada approval for five additional flowering rooms totaling 50,000 sq ft of additional production space at its facility in Kincardine, Ontario. Total flowering room space at 7ACRES increases from 180,000 sq ft to 230,000 sq ft and 7ACRES’ annual production capacity estimate increases from approximately 26,250kg to 33,580kg. As noted previously, Supreme Cannabis expects to realize further production efficiencies following the licensing of all 25 flowering rooms, whereby 7ACRES’ potential capacity is anticipated to reach approximately 50,000kg. “With five more flowering rooms at 7ACRES now approved by Health Canada, the finish line is in sight,” said John Fowler, President and Founder of Supreme Cannabis.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensated twenty-five hundred dollars for news coverage of the current press release issued by RavenQuest BioMed Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: email@example.com – +1(561)325-8757